Login to Your Account



Pharma: Clinic Roundup


Tuesday, May 21, 2013
• Cempra Inc., of Chapel Hill, N.C., presented data at the American Thoracic Society International Conference (ATS 2013) in Philadelphia demonstrating the antibacterial and enhanced immunomodulatory activity of solithromycin vs. levofloxacin in Cempra's prior Phase II trial in outpatients with community acquired bacterial pneumonia (CABP).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription